Events & Presentations
Events
-
Sirnaomics Ltd. 2023 Interim Results Presentation
01 Sirnaomics-Dr Dai Xiaochang-Embracing a New Era of RNA Medicine, Biopharma Innovation in the Greater-Bay Area.mp42023-09-2802 Sirnaomics- Dr Lu Yang Advancing Delivery Technology for Innovative RNAi Therapeutics, from Benchtops to Bedsides.mp42023-09-2803 Sirnaomics-Dr Dai Xiaochang-Embracing a New Era of RNA Medicine, Biopharma Innovation in the Greater-Bay Area.mp42023-09-2804 Sirnaomics- Dr Lu Yang Advancing Delivery Technology for Innovative RNAi Therapeutics, from Benchtops to Bedsides.mp42023-09-2805 Sirnaomics-Dr Dai Xiaochang-Embracing a New Era of RNA Medicine, Biopharma Innovation in the Greater-Bay Area.mp42023-09-2801 Sirnaomics-Dr Dai Xiaochang-Embracing a New Era of RNA Medicine, Biopharma Innovation in the Greater-Bay Area.mp42023-09-2802 Sirnaomics- Dr Lu Yang Advancing Delivery Technology for Innovative RNAi Therapeutics, from Benchtops to Bedsides.mp42023-09-2803 Sirnaomics-Dr Dai Xiaochang-Embracing a New Era of RNA Medicine, Biopharma Innovation in the Greater-Bay Area.mp42023-09-2804 Sirnaomics- Dr Lu Yang Advancing Delivery Technology for Innovative RNAi Therapeutics, from Benchtops to Bedsides.mp42023-09-2805 Sirnaomics-Dr Dai Xiaochang-Embracing a New Era of RNA Medicine, Biopharma Innovation in the Greater-Bay Area.mp42023-09-28
- Sirnaomics Ltd. 2022 Annual Results Presentation
- Sirnaomics Ltd. 2022 Interim Results Presentation
- Sirnaomics Ltd. 2021 Annual Results Presentation – Transcript
- Sirnaomics Ltd. 2021 Annual Results Presentation
Presentations
- Sirnaomics Ltd. 2023 STP705 isSCC Clinical Phase Update
- Sirnaomics Ltd. 2023 STP705 Fat Remodeling interim results
- Sirnaomics Ltd. 2022 Interim Data Release for STP705 isSCC&STP707 Solid Tumo
- 2022RNATx: GalAhead™: a novel therapeutic GalNAc-RNAi platform to downregulate single and multiple genes
- 2022OPT: GalNAc-Based Liver-Targeting Platforms and Product Pipeline